Neurogene (NGNE) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Expected Q1 2026 results: Neurogene will report earnings before the market on May 7, with analysts forecasting EPS of ($1.35); the company will host a call May 8 at 4:00 PM ET and last quarter beat estimates (reported ($1.12) vs. consensus ($1.20)).
• Shares opened at $26.48 and are down recently, with a 12‑month range of $11.77–$37.27 and a market cap of about $414M; analysts project negative EPS (~$-5) for the current and next fiscal year and the stock carries a negative P/E.
• Insider and analyst signals: insiders (including Stuart Cobb and CFO Christine Mikail Cvijic) sold shares in March and insiders now own ~9.9% while institutions own ~52.4%; analyst coverage is mixed but the consensus is a "Moderate Buy" with a $67 price target (6 Buys, 1 Hold, 1 Sell).

Neurogene (NASDAQ:NGNE - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.35) per share for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.08. On average, analysts expect Neurogene to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Neurogene Trading Down 3.5%

Shares of NASDAQ NGNE opened at $26.48 on Thursday. Neurogene has a twelve month low of $11.77 and a twelve month high of $37.27. The company has a market capitalization of $413.62 million, a price-to-earnings ratio of -6.25 and a beta of 1.56. The firm has a 50-day moving average of $22.14 and a two-hundred day moving average of $22.22.

Insider Transactions at Neurogene

In other Neurogene news, insider Stuart Cobb sold 6,797 shares of the company's stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the sale, the insider directly owned 30,497 shares of the company's stock, valued at approximately $634,642.57. This represents a 18.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the company's stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the sale, the chief financial officer directly owned 105,798 shares of the company's stock, valued at $2,201,656.38. This represents a 3.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.92% of the stock is currently owned by corporate insiders.

Institutional Trading of Neurogene

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock valued at $82,000 after purchasing an additional 1,059 shares in the last quarter. Bank of America Corp DE grew its position in Neurogene by 81.6% during the second quarter. Bank of America Corp DE now owns 95,401 shares of the company's stock valued at $1,426,000 after purchasing an additional 42,880 shares in the last quarter. BNP Paribas Financial Markets grew its position in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company's stock valued at $36,000 after purchasing an additional 978 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in Neurogene during the third quarter valued at approximately $187,000. Finally, Balyasny Asset Management L.P. purchased a new position in Neurogene during the third quarter valued at approximately $12,114,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on NGNE shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Neurogene in a research note on Tuesday, April 21st. Guggenheim started coverage on shares of Neurogene in a research note on Tuesday. They set a "buy" rating and a $69.00 price objective for the company. Lifesci Capital started coverage on shares of Neurogene in a research note on Monday, January 26th. They set an "outperform" rating and a $50.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Neurogene in a research note on Tuesday, January 13th. Finally, Canaccord Genuity Group reduced their price objective on shares of Neurogene to $180.00 and set a "buy" rating for the company in a research note on Monday, April 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Neurogene currently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.